Prof. Harkishan Singh

Professor Harkishan Singh, (25th November 1928 - 20th March 2020) was Professor Emeritus at the Panjab University (Chandigarh, India), is a well recognized pharmaceutical academic, medicinal chemistry researcher and a science historian. He has experience of over half a century to his credit. He has worked at the Banaras Hindu University, University of Saugar and Punjab University in India, and abroad at the University of Maryland, University of Mississippi and the University of London. His scientific research has been in organic chemistry, medical chemistry and natural products. Nearly 50 master and doctoral theses have been completed under his supervision. There have been published 125 original scientific research papers. 14 patents have been obtained. His research group has been successful in designing a clinically useful drug candocuronium iodide (INN) (chandonium iodide, HS-310), which is a synthetic azasteroid. Dr Singh has lectured on his research at several of the institutions and conferences in India, United States of America, Canada, United Kingdom, Switzerland and China. He delivered invited lectures at the Harvard School of Medicine and at the International Symposium on Molecular Structure sponsored by the International Union of Crystallography at Beijing. As a science historian Professor Singh has examined the history of pharmaceutical developments in India of the nineteenth and twentieth centuries. His history research studies have been on pharmacopoeias and formularies, pharmaceutical education, pharmacy practice, biographies of pharmaceutical luminaries, and pharmaceutical journalism. He has published over eighty articles. All told his total publications come to well over 350, including eighteen books. Selected publications are listed later. Professor Singh has been on many academic, scientific, professional and governmental bodies. He was a member of the Committee on International Education of Medicinal Chemists of the International Union of Pure and Applied Chemistry, which prepared the Report on the International Education of Medicinal Chemists (IUPAC Technical Reports Number 13; 1974). His affiliations with several scientific and professional organizations include emeritus membership of the American Chemical Society, life memberships of the Indian Pharmaceutical Association and Association of Pharmaceutical Teachers of India, and memberships of the American Institute of History of Pharmacy and British Society for History of Pharmacy. Professor Harkishan Singh was a recipient of several scientific and professional awards and recognitions. He has been a National Fellow of the University Grants Commission, New Delhi. He has been General President of the Indian Pharmaceutical Congress. He received Eminent Pharmacist Award of the Indian Pharmaceutical Association. Lifetime achievement awards have been conferred on him by several bodies; the recent one is the Lifetime Achievement Award by the Punjab Academy of Sciences. Dr Singh's standing as historian has been recognized through his election to the Academie Internationale d'Histoire de la Pharmacie. The University of the Sciences in Philadelphia conferred upon Professor Harkishan Singh the degree of Doctor of Science (Honoris Causa) in recognition of his distinguished academic career and outstanding contributions to scientific research in organic and medicinal chemistry and the history of pharmacy. Candocuronium (Chandonium), A Neuromuscular Blocker Discovery The research papers and reviews marked with asterisk under Medicinal Chemistry and Allied Fields refer to synthetic azasteroidal neuromuscular blockers and related aspects. A new neuromuscular blocker, initially named as Chandonium Iodide, was designed and synthesized by the research group of Professor Harkishan Singh at the Panjab University, Chandigarh. The pharmacological testing was carried out at the University at Strathclyde. The toxicity studies at the Central Drug Research Institute, Lucknow, did not reveal any adverse effects. The clinical studies were also successfully completed through the CDRI. The proceedings of the symposium on the clinical testing on Chandonium Iodide were published in the Journal of Anaesthesiology and Clinical Pharmacology, 10, 109-151 (1994). The drug was cleared by the Ministry of Health, Government of India, for manufacturing and clinical use. The World Health Organization gave to the drug the INN designation Candocuronium Iodide. The drug is a potent non-depolarizing neuromuscular blocker with short duration of action. The injections can be sterilized by autoclaving. The preparation can be stored at room temperature without any loss of activity.

Khwaja Abdul Hamied

Khwaja Abdul Hamied (31 October 1898 – 23 June 1972) was an Indian industrial and pharmaceutical chemist who founded Cipla, India's oldest pharmaceutical company in 1935. His son, Yusuf Hamied headed the company after him for the next 52 years. Khwaja Abdul Hamied was active in the Indian independence movement and a champion of composite nationalism. Early life and background - Hamied was born in Aligarh, to Khwaja Abdul Ali, an advocate, and Masood Jahan Begum. Through his father, he was descended from the Sufi saint Khwaja Ahrar of iran (Uzbekistan), while on his mother's side, he was descended from Shah Shuja, the last Durrani king of Afghanistan. His paternal great-uncle was the noted reformer Sayyid Ahmad Khan he was also the grandnephew of Khwaja Muhammad Yusuf and a nephew to Abdul Majeed Khwaja. Education - After matriculating from Islamia High School, Etawah, distinguishing himself in mathematics, Hamied completed his Intermediate in Science from Agra College in 1917. Having decided to become a chemist, he then spent a year at a Madras trade school studying leather technology before enrolling at Muir Central College in Allahabad, from which he completed his B.Sc. in chemistry in 1920. While at the college, he became a favourite student of Nil Ratan Dhar, a distinguished inorganic chemist under whom he studied for a master's degree. He graduated from Allahabad University in Allahabad, Uttar Pradesh and held M.A. and PhD degrees from the Humboldt University of Berlin in Germany. He was a disciple of M.K. Gandhi and former founder professor along with Zakir Husain of the Jamia Milia Islamia in Aligarh, now based in Delhi. Career - Hamied's family raised money to send him to study chemistry in England, during British rule, in 1924. Instead, he changed ships and went to Germany, then the world's leader in chemicals. On a Berlin lake, he met a Lithuanian Jewish socialist, whom he married. They fled as the Nazis rose to power in Germany. Chemical, Industrial and Pharmaceutical Laboratories, Cipla was founded in 1935 with an initial capital of Rs. 2 lakhs. The company commenced production in 1937 making it the oldest pharmaceutical company in India. His eldest son Yusuf Hamied, who did study chemistry in England, is now Chairman of Cipla. Yusuf still refers to his chemistry notebooks from Cambridge. Apart from conceiving the idea of establishing a National Chemical Laboratory and making it a reality, Dr Khwaja Hamied floated the idea and conceptualized the establishment of the Council of Scientific and Industrial Research (CSIR) as an umbrella organization to run a clutch of laboratories. He remained a Member of the Governing Body of the CSIR right from its inception till the very last. During the last four decades of his life, he played an important role in raising the pharmaceutical and chemical industry standards in India to an extraordinarily high level through founding the firm Cipla. Dr. Hamied was an honorary professor and a member of the executive council of the Aligarh Muslim University, member of the Senate of Bombay University and a fellow of the Royal Institute of Chemistry, UK. He was also a member of the Bombay Legislative Council from 1937 to 1962, refusing the offer of becoming a Muslim Minister in the cabinet in Bombay. Hamied also served as Sheriff of Bombay. Dr Khwaja Abdul Hamied died in 1972 after a brief illness.

CL Kaul

He was born on October 10, 1936. He graduated with a B. Sc. from the Panjab University, Chandigarh in 1956 and a B. Pharm. from the prestigious L. M. College of Pharmacy in Ahmedabad in 1959. Subsequently, he completed his Doctor of Philosophy from the University of Glasgow, Scotland in 1964. After a brief Postdoctoral work at the University of Glasgow in 1964, he returned to India and started his career in the Ciba-Geigy Research Centre in Bombay in 1965 and served in various capacities till 1979. He then joined the Boots Pharmaceuticals, Bombay as a research manager in 1979, became the director, research in 1984 and then the director, research and development in 1987. He joined the National Institute of Pharmaceutical Education and Research (NIPER) as the Founder Director on September 1, 1994, and was involved in shaping that institute to international repute for a decade till his retirement in 2004. Dr. Kaul’s research over a period of 4 decades involved discovery and pre-clinical development of new drugs, development of pharmaceutical formulations that included stability evaluations and bioavailability studies. Many new chemical entities under his able supervision reached different phases of clinical development and two of which have received approval for marketing. Dr. Kaul has published around 150 research papers in peered review journals, 20 patents and 4 book chapters. Dr. Kaul was very active professionally and contributed immensely to the pharmaceutical profession through the Indian Pharmaceutical Association (IPA). Dr. Kaul's contributions to IPA were phenomenal. He was the Hon. Gen. Secretary during 1988-92, a Vice President of IPA during 1992-94 and the President of IPA during 1994- 96. Dr. Kaul received the prestigious IPA Fellowship in 2000 followed by the coveted Eminent Pharmacist Award in 2002. Dr. Kaul initially served as an editorial board member of IJPS, then as the associate editor from 1986-92. He was the editor of IJPS during 1992-96. In 1996 Dr. Kaul relinquished the editor position and served the journal as an advisory board member till his untimely demise. We at IJPS, condole the sad demise of Dr. C. L. Kaul and pay our respects and tribute to Dr. C. L. Kaul for his stupendous contribution to the pharmacy profession.

Mr. B N Thakore

He was Quality Control Manager at Pfizer Ltd. & later promoted as “Compliance Head” before retirement from Pfizer.

After retirement he founded his own Co. called Morris Lab at Ankleshwar.

He was IPA President from 1984-86.
Before that he was very much involved with IPA in different capacities.
He along with other members established strong foundation of IPA.
He was actively involved in Indian Pharmacopeia - 95 version, monograph amendments.

Vinay Thakur

Vinay Thakur, a pharmacist of repute who won a gold medal during his B Pharm and M Pharm and carried a rich industrial experience. Wanted to change the approach of quality of products produced at third party manufacturing locations. Realised this dream through his firm Mistair Pharma, setting a trend of uncompromising global pharmaceutical standards amongst TPMs. He would often say ' Cost is a fact, price is a policy and quality is the gospel reality. The team Mistair now treads the path of this philosophy.

Uttambhai Nathalal Mehta

Uttambhai Nathalal Mehta (1924 - 1998) was an Indian businessman and the founder and chairman of Torrent Group.

Early and personal life
Mehta was born in Mehmadpur, a small village in Palanpur district, India, in Gujarati Jain family. After finishing his primary education in Palanpur, moved to Mumbai, where he completed his B.Sc. from Wilson College, while staying at the Mahavir Jain Vidyalay hostel.

Mehta and his wife Shardaben, had four children, sons Sudhir and Samir, and daughters Meena and Nayna

Career
He started his career as a government servant in 1944. He worked as a medical representative for the pharmaceutical company Sandoz from 1945 to 1958.

Then in 1959 he took the path breaking decision to start his own firm Trinity Laboratories with a seed capital of just Rs 25,000. This organization began to manufacture special medicines. In 1968, Mehta began to market a medicine for treatment of mental diseases.

It was a big step at a time when only multinational companies manufactured specialty drugs, and subsequently Mehta went on to establish Torrent Laboratories in 1976. The company began marketing a number of drugs at competitive prices and soon made a name for itself. Today, Torrent is a large company engaged in the business of pharmaceutical goods and power generation.

Awards and recognition
He was conferred with numerous felicitations, including the ‘Business Man of the Year’ award in 1996-97 from the Government of India. Torrent has also won many awards for in manufacturing, exporting and marketing.

U. N. Mehta Institute of Cardiology and Research Centre (UNMICRC) at Ahmedabad, Gujarat is named after him. Over the years, Torrent group has provided sizeable financial contribution, which has been used for constructing a 450-bedded facility. Apart from Hospital Infrastructure development, Torrent’s Patient Care Initiative Programme at UNMICRC has resulted in effective service delivery and better hospital management. The treatment is rendered to all patients, particularly the economically disadvantaged. Free Cardiac treatment is provided to Gujarat domiciled children and patients from the weaker strata

Mr. Upendra Madan Deshpande

Mr. Upendra Madan Deshpande, born on April 30, 1963, was a distinguished leader in the pharmaceutical industry, serving as the Director of Milan Laboratories (India) Pvt. Ltd. since March 26, 2003. ​

Under his guidance, Milan Laboratories expanded its global footprint, exporting pharmaceutical formulations to over 43 countries and securing more than 300 marketing authorizations worldwide. The company's facilities achieved approvals from stringent regulatory authorities, including the UK-MHRA and South Africa's MCC, reflecting Mr. Deshpande's commitment to maintaining high-quality standards.​

Mr. Deshpande's leadership was instrumental in Milan Laboratories' recognition as a Government Recognized Star Export House and its receipt of various awards for quality excellence and outstanding export performance. His dedication to innovation and excellence significantly contributed to the company's growth and success in the competitive pharmaceutical sector.​

Beyond his professional achievements, Mr. Deshpande was known for his joyfulness, generosity, and commitment to fitness. His sudden passing on March 8, 2025, due to a cardiac arrest, was a profound loss to all who knew him. His legacy continues to inspire those at Milan Laboratories and the broader pharmaceutical community. ​

Sanjeev I. Dani

Sanjeev I. Dani was a distinguished figure in the pharmaceutical industry, renowned for his extensive contributions over a career spanning several decades. He held pivotal roles in major pharmaceutical companies, including a significant tenure at Ranbaxy Laboratories, where he managed various markets such as India, the Middle East, Asia Pacific, and Africa. ​

In August 2015, Mr. Dani joined Aurobindo Pharma as the Chief Operating Officer (COO) and Head of Formulations. In this capacity, he led the front-end operations of emerging markets and Europe, playing a crucial role in steering the company's strategic direction and operational excellence. ​

Tragically, on November 21, 2023, the pharmaceutical community mourned the loss of Mr. Dani. His passing marked a poignant moment for the industry, as he had been a driving force in shaping the pharmaceutical landscape through his leadership and vision. ​

Mr. Dani's legacy is characterized by his dedication to advancing the pharmaceutical sector, his strategic acumen, and his commitment to fostering growth in the markets he oversaw. His contributions have left an indelible mark on the industry, inspiring future generations of pharmaceutical professionals.

Samprada Singh

Samprada Singh (1925 – 27 July 2019) was a pioneering Indian entrepreneur and founder of Alkem Laboratories, one of India's leading pharmaceutical companies. Born in Okri village, Jehanabad, Bihar, Singh graduated with a Bachelor of Commerce degree from Patna University. His initial venture into the pharmaceutical industry began in 1953 with a small chemist shop near Patna Medical College and Hospital. This modest beginning laid the foundation for his future endeavors in the pharmaceutical sector. ​
In 1973, Singh founded Alkem Laboratories in partnership with his younger brother, Basudeo Narayan Singh. Under his visionary leadership, Alkem expanded its operations globally, establishing a significant presence in Europe, Africa, the Asia Pacific, South America, and the United States. The company's growth was marked by its commitment to developing, manufacturing, and marketing high-quality pharmaceutical formulations and nutraceuticals. Singh's strategic direction and dedication were instrumental in positioning Alkem as a major player in the global pharmaceutical industry. ​

Throughout his illustrious career, Singh received numerous accolades recognizing his contributions to the pharmaceutical sector. In 2009, he was honored with the Lifetime Achievement Award at the Pharmaceutical Leadership Summit & Awards. In 2017, he received the Ernst and Young 'Entrepreneur of the Year in Healthcare and Life Sciences' award. That same year, Forbes India ranked him as the 43rd richest individual in the country, with an estimated net worth of $3.3 billion. ​

Singh's journey from a small chemist shop to leading a global pharmaceutical giant exemplifies entrepreneurial spirit and dedication. His legacy continues to inspire future generations in the pharmaceutical industry. Singh passed away on 27 July 2019 at the age of 94, leaving behind a lasting impact on the industry he helped shape.

Ranjit Shahani

Ranjit Shahani was a renowned leader in the pharmaceutical industry, best known for his role as the Former Vice-Chairman and Managing Director of Novartis India Ltd. He played a crucial role in shaping Novartis’ presence in India, leading the company through various regulatory and market challenges. Before joining Novartis in 1997, he had an illustrious career with major global corporations such as Roche and ICI Zeneca, where he held leadership roles in diverse industries, including petrochemicals, plastics, and healthcare. His experience across sectors gave him a broad perspective, which he applied effectively in the pharmaceutical space.

During his tenure at Novartis, Mr. Shahani was instrumental in handling one of the biggest patent disputes in Indian pharmaceutical history over the cancer drug Glivec. His calm and composed leadership during this high-stakes battle earned him significant respect within the industry. Beyond Novartis, he was actively involved in industry organizations, serving as President of the Organisation of Pharmaceutical Producers of India (OPPI) and President of the Swiss Indian Chamber of Commerce. He was also a key figure in shaping pharmaceutical policy and advocating for industry growth in India.

Apart from his corporate achievements, Mr. Shahani contributed significantly to various boards, including JB Chemicals & Pharmaceuticals, Hikal Ltd, and Ambuja Cements. His influence extended beyond pharmaceuticals into other industries, where his strategic guidance and leadership were highly valued. His expertise and business acumen made him a sought-after advisor for many organizations.

Ranjit Shahani passed away on March 9, 2024, at the age of 74, leaving behind a remarkable legacy. He was known not just for his business achievements but also for his mentorship, generosity, and ability to navigate complex industry landscapes. His contributions to the pharmaceutical sector in India were transformative, and his leadership continues to inspire professionals in the field.

Ramanbhai B. Patel

Ramanbhai B. Patel (19 August 1925 – 19 September 2001) was an influential Indian chemist and entrepreneur, best known for founding Cadila Laboratories, which evolved into one of India's leading pharmaceutical companies. Born in Kathor, South Gujarat, Patel pursued a degree in chemistry at Gujarat University's L.M. College of Pharmacy. He began his career as a lecturer before venturing into the pharmaceutical industry. ​

In 1952, Patel co-founded Cadila Laboratories with his school friend Indravadan Modi. Under his visionary leadership, the company made significant strides in the pharmaceutical sector. Notable achievements include the production of Isopar, a formulation of anti-tuberculosis drugs, in 1957, and Neuroxin-12, a single-vial mixture of vitamins B1, B6, and B12, in 1959. The firm also developed process technology for the anti-diabetic drug glibenclamide in 1973 and launched Dexona-20, a concentrated form of the anti-inflammatory drug dexamethasone, in 1977. ​

Patel's contributions to the pharmaceutical industry and education were widely recognized. He received several prestigious awards, including the President of India's Import Substitution Award in 1973, the Prof. M.L. Shroff Memorial National Award in 1987, the Glory of India Award in 1991 in Washington, the Grahak Suraksha Award in 1992, the Acharya Prafulla Chandra Ray Memorial Gold Medal in 1993, and the Eminent Pharmacist Award in 1994. In 2000, he was honored as the Gujarat Businessman of the Year. ​

Beyond his industrial achievements, Patel was committed to advancing pharmaceutical education, particularly in Gujarat's rural areas. His efforts led to the establishment of several reputed pharmacy colleges, making professional courses more accessible to students in smaller towns. In recognition of his lasting impact, the Indian Pharmaceutical Association, in collaboration with the Ramanbhai B. Patel Foundation, instituted the IRF Life Time Achievement Award in 2003 to honor senior pharmacists who have made noteworthy contributions to the field. ​

Patel's legacy continues through Cadila Healthcare, now known as Zydus Lifesciences, under the leadership of his son, Pankaj R. Patel. The company remains a testament to his vision of providing affordable, high-quality medicines, significantly contributing to the accessibility of healthcare in India and beyond.

Dr. Parvinder Singh

Dr. Parvinder Singh was a visionary leader who played a pivotal role in transforming Ranbaxy Laboratories into a global pharmaceutical powerhouse. Born into a family with business acumen, he pursued higher education in pharmacy, earning a master's degree from Washington State University and a Ph.D. from the University of Michigan. In 1967, he joined Ranbaxy, a company founded by his father, Bhai Mohan Singh, and quickly became instrumental in its evolution from a domestic enterprise to an international entity.

Throughout his illustrious career, Dr. Singh was recognized for his contributions to the pharmaceutical industry. He was instrumental in making Ranbaxy the first Indian pharmaceutical company to break into the U.S. and European markets with its generic drugs. His efforts in promoting research and development led to the establishment of state-of-the-art R&D facilities in India. Under his leadership, Ranbaxy received numerous global regulatory approvals, including those from the U.S. Food and Drug Administration (FDA), making it a credible player in the international market.

Dr. Singh's leadership style was characterized by a blend of traditional values and modern management practices, fostering a culture of excellence and integrity within the organization. He was a key advocate for Indian pharmaceutical self-reliance and was instrumental in shaping policies that encouraged indigenous research and production. His contributions to the industry earned him respect among peers, and he was often regarded as a trailblazer who set high standards in corporate governance and ethical business practices.

Tragically, Dr. Parvinder Singh passed away in 1999, but his legacy endures. He is remembered not only for his business acumen but also for his commitment to ethical practices and corporate governance. His contributions laid the foundation for Ranbaxy's subsequent growth and have been a source of inspiration for future generations of business leaders in India.

Mahadeva Lal Schroff

Prof. Mahadeva Lal Schroff is regarded as India's founder of pharmacy. He attained this distinction as a result of his accomplishments, which included steering India's pharmaceutical sector and educational system in the proper direction. Furthermore, despite the fact that he was not even a professional pharmacist, he had a huge influence on the pharmaceutical sector.

Prof. Mahadeva Lal Schroff is known as the Father of Pharmacy Education in India because he steered the field of pharmacy in the correct direction and inspired several generations of pharmacists. He wasn't a qualified pharmacist, but his contributions to the industry are many, and he fostered the field to provide opportunities for future pharmacists. Throughout his life and profession, he faced several barriers and major problems.

Prof. Mahadeva Lal Schroff was born in the Bihar city of Darbhanga on March 6, 1902. He finished his education at Bhagalpur (Bihar) and passed his intermediate test in 1920. Following that, he enrolled in the Engineering College at Banaras Hindu University (BHU) in Varanasi, India. Prof. Schroff was ordered to leave the institution in 1921 after speaking out against the then-principal, Charles A. King. Prof. Schroff left India after graduating from engineering school and spent time in China, Japan, and America. He earned his UG degree in arts with honors in chemistry in 1925 and his PG degree in chemistry and microbiology from the Massachusetts Institute of Technology (MIT) in 1927.

Prof. Mahadeva Lal Schroff, properly referred to as the Father of Pharmacy Education in India, passed away on August 25, 1971, and he surely remains an inspiration to all pharmacists working in this nation, regardless of their branches or responsibilities. Prof. Schroff, who was not qualified as a pharmacist, guided not just pharmaceutical education but also the Indian industry with his aptitude, comprehension, talent, and broad vision.

The following are some of the things which are founded by Prof. Mahadeva Lal Schroff-

Indian Pharma Association (1935 as the U.P. Pharma Association and 1939 as the Indian Pharmacy Association).
Indian Journal of Pharmacists (1945).
Bhaishaj Patrika in Hindi (1980).
Bheshjayan (1968).
Indian Pharmaceutical Congress (1968).
President of various State Pharmacist Associations (Bengal, Bihar).
President of the Pharmacy Council of India (1954-1959).

His work, "The History of Indian Pharmacy," is a classic treatise that unfolds the numerous features of pharmacy practice in ancient and medieval India, which have roots and significance even in current pharmacy in our nation. Prof. Mahadeva Lal Schroff's life inspires us to work hard, be sincere in our intentions, and serve the homeland. As the pioneer who lighted the fire of pharmaceutical education in the country, he will remain an inspiration to Indian pharmacists.

Krishan Kumar Arora

Mr. Krishan Kumar Aurora, a distinguished figure in the Indian pharmaceutical industry, passed away on December 23, 2024, at the age of 88. His career, spanning over six decades, was marked by transformative leadership and significant contributions to healthcare.​

Mr. Aurora began his professional journey as an accountant with A.F. Ferguson & Co., before moving on to Boots Pure Drug Co. (India) Ltd. In 1961, he joined Smith Kline & French (India) Ltd., where he ascended to the position of Managing Director and later became the International Vice President for Southeast Asia. His tenure at Smith Kline & French showcased his adeptness in navigating complex markets and his commitment to pharmaceutical excellence.​

In 1990, Mr. Aurora took over Pharmed Limited, transforming it into a trusted and respected name in the Indian pharmaceutical industry. Under his stewardship, Pharmed and the BioPlus Group became synonymous with innovation, quality, and excellence, earning accolades from healthcare providers. ​

Beyond his corporate achievements, Mr. Aurora played pivotal roles in industry organizations. As President of the Bangalore Chamber of Industry and Commerce (1988-89), he spearheaded significant initiatives, including establishing the Chamber’s first office in Bangalore and advocating for industrial reliefs on taxes and levies for captive power generation. In 2023, the Karnataka Drugs & Pharmaceuticals Manufacturers Association honored his unparalleled contributions to the pharmaceutical industry, celebrating his unwavering dedication and relentless pursuit of excellence.

Jagdish Kantisarup Saxena

Jagdish Kantisarup Saxena was an influential figure in India's pharmaceutical industry, best known as the founder of Elder Pharmaceuticals. His journey from an employee to a successful entrepreneur is both inspiring and instructive.​

Saxena's entrepreneurial journey began unexpectedly. After the pharmaceutical division of his employer in Delhi shut down, he chose to start his own venture, leading to the establishment of Elder Pharmaceuticals in 1989. Under his leadership, the company flourished, becoming a significant player in the pharmaceutical sector. ​

Beyond his business endeavors, Saxena was a family man. He is survived by his wife, Sneh, and their three children: sons Alok and Anuj, and daughter Shalini. His son, Anuj Saxena, is a multifaceted personality known for his roles as an actor, producer, businessman, and restaurateur. ​
StarsUnfolded

Saxena's legacy is a testament to resilience and vision. His journey underscores the impact of seizing unforeseen opportunities and transforming challenges into successful ventures.

Indravadan Ambalal Modi

Indravadan Ambalal Modi (18 February 1926 – 26 November 2012) was a pioneering Indian industrialist, renowned for his substantial contributions to the pharmaceutical sector. Born in Hansot, Bharuch district, Gujarat, he earned the moniker "Medicine Man of India" due to his relentless pursuit of making healthcare accessible and affordable. ​

Modi's commitment to ethical business practices and innovation was evident throughout his career. He emphasized the importance of clean and ethical practices, instilling these values within his company. His strategic decisions, particularly significant investments in research and development, led to the introduction of groundbreaking products like Polycap for heart disease prevention and Risorine for tuberculosis treatment. ​

Beyond his corporate achievements, Modi was deeply committed to philanthropy. Motivated by personal loss, he established the Kakaba and Kala-Budh Public Charitable Trust, under which he inaugurated a 30-bed hospital in Hansot to provide modern healthcare to underserved populations at reduced costs. ​

Modi's exemplary contributions garnered numerous accolades, including the Lifetime Achievement Award from the Gujarat Chamber of Commerce and Industry in 2005, the Express Pharma Pulse Lifetime Achievement Award, and the Indian Pharmaceutical Association's Ramanbhai Patel Foundation Lifetime Achievement Award. His enduring legacy continues to inspire advancements in India's pharmaceutical industry, reflecting his unwavering commitment to healthcare and societal well-being.

Gracias Saldanha

Gracias Saldanha (1938 – 21 July 2012) was an Indian businessman and the founder of Glenmark Pharmaceuticals, a leading entity in the pharmaceutical industry. Born in Saligão, Goa, Saldanha pursued higher education in science, earning a master's degree from Bombay University. Before establishing his own venture, he accumulated over 12 years of experience working with various pharmaceutical companies, which laid the foundation for his entrepreneurial journey. ​

In 1977, Saldanha founded Glenmark Pharmaceuticals, naming the company after his two sons, Glenn and Mark. The company began as a manufacturer of generic drugs and active pharmaceutical ingredients, initially serving markets in India, Russia, and Africa. Under his leadership, Glenmark expanded its global footprint and diversified its product offerings, evolving into a significant player in the pharmaceutical sector. ​

Saldanha's commitment to innovation and quality propelled Glenmark's growth. He remained actively involved in the company's operations for over three decades, retiring as Chairman and Non-Executive Director in 2011. His legacy continues through his sons: Glenn Saldanha, who currently serves as the Managing Director and Chairman of Glenmark Pharmaceuticals, and Mark Saldanha, the owner and CEO of
Gracias Saldanha passed away on 21 July 2012 in Mumbai, Maharashtra, leaving behind a legacy of entrepreneurial spirit and significant contributions to the pharmaceutical industry. ​

Gracias Saldanha, the founder of Glenmark Pharmaceuticals, received several accolades during his illustrious career. Notably, in 2010, he was honored as the "Forbes Asia Businessman of the Year," recognizing his significant contributions to the pharmaceutical industry. ​
goansw.org

In 2011, Saldanha was listed at the 69th position on Forbes's list of Indian billionaires, with an estimated net worth of $805 million, reflecting his success and impact in the business world. ​
StartupTalky

His leadership also led Glenmark Pharmaceuticals to receive industry accolades, including the "SCRIP Award" for 'Best Company in Emerging Markets,' further cementing his legacy in the global.

G.C. Burman

Gyan Chand (G.C.) Burman was a pivotal figure in the history of Dabur India Limited, one of India's leading consumer goods companies known for its Ayurvedic products. As the Vice-Chairman and Managing Director, he played a significant role in steering the company towards growth and diversification. Under his leadership, Dabur expanded its product range and solidified its presence in both domestic and international markets.​

G.C. Burman passed away on September 7, 2001, due to a heart attack. His death marked the end of an era for the company, but his legacy continued through the next generation of the Burman family. Following his demise, his son, Amit Burman, joined the Dabur India board, increasing the number of Burman family members on the board from five to six. This transition ensured that the company's leadership remained within the family, maintaining the vision and values established by its founders.​

Today, Dabur India Limited stands as a testament to the Burman family's dedication and strategic vision. The company has evolved into a global leader in Ayurvedic and natural products, offering a wide range of items from health supplements to personal care products. The foundation laid by G.C. Burman and his predecessors has been instrumental in shaping Dabur's journey, reflecting a legacy of innovation, resilience, and commitment to quality.

G.C. Surana

G.C. Surana was a visionary entrepreneur and the founder of Micro Labs Limited, a prominent Indian pharmaceutical company. His journey in the pharmaceutical industry began with his association with a pharmaceutical distributor in Bangalore, which laid the foundation for his future endeavors. In 1973, he established Micro Labs in Chennai, leveraging his extensive experience and insight into the industry's potential. ​

Under Surana's leadership, Micro Labs expanded its footprint across India, establishing 14 state-of-the-art manufacturing facilities and three research and development centers employing over 300 dedicated scientists. The company's growth was further propelled by a robust sales team of more than 5,000 medical representatives, reaching over 250,000 doctors and 180,000 pharmacies nationwide. This strategic expansion positioned Micro Labs among the top pharmaceutical companies in India, ranking 10th in prescriptions and 20th in sales in the local market. ​

Surana's legacy is also reflected in his family's continued involvement in the business. His sons, Dilip Surana and Anand Surana, took over the company's operations in the 1980s and 1990s, respectively. Dilip currently serves as the Chairman and Managing Director, while Anand holds the position of Director. Their leadership has been instrumental in steering Micro Labs toward further growth and innovation, maintaining the visionary path laid by their father. ​

Beyond his business acumen, G.C. Surana was known for his commitment to quality and affordable healthcare. His dedication to excellence not only established Micro Labs as a reputable pharmaceutical company but also contributed significantly to the accessibility of essential medicines in India and beyond. Surana's entrepreneurial spirit and commitment to societal well-being continue to inspire and guide the company's ethos and operations.

Suresh Jadhav

Suresh Jadhav (1948/49 – 7 December 2021) was an Indian biotechnology executive and a key member of the Indian vaccine manufacturing industry. At the Serum Institute of India (SII) he led the development and introduction of the Meningococcal A conjugate vaccine to Sub-Saharan Africa and the production of the COVID-19 vaccine at SII, including the ones marketed as Covishield.

Jadhav was a member of the board of the GAVI vaccine alliance, and a member of the Indian government's expert committee on vaccines and other biologicals and a member of the Indian Pharmacopoeia Commission.

Jadhav was born in a village in Vidarbha in the eastern part of the Indian state of Maharashtra.[2] He completed his master's degree in pharmacy and later obtained a PhD from the Nagpur University.

He started his career in 1970 with a research fellowship at the Council of Scientific and Industrial Research (CSIR) before moving to the academia and teaching at the Department of Pharmaceutical Sciences, Nagpur, SNDT women's university, and the Haffkine Institute in Bombay.

Jadhav joined the Serum Institute of India (SII) in 1979, where he was responsible for manufacturing, laboratory and clinical practices, and quality control. He has been recognized as one of the contributors to SII being established as the world's largest vaccine manufacturer in the world. He became an executive director at the institute in 1992 and was responsible for manufacturing and quality control. He set up the institute's manufacturing facilities in Manjri near Pune. During his time at the SII, he led the development and introduction of the Meningococcal A conjugate vaccine to Sub-Saharan Africa. He also contributed to SII's acquisition of Bilthoven Biologicals in the Netherlands.

Jadhav's actions contributed to SII securing the World Health Organization accreditation for various vaccines enabling the company to export its vaccines to governments and health organizations across 140 countries. He was also a contributor to the Expanded Program on Immunization and had driven the partnership between the Bill and Melinda Gates Foundation and SII. Jadhav was also a member of the leadership team that worked on producing the COVID-19 vaccine at SII, including the ones marketed as Covishield.

Jadhav was also a member of various professional bodies and committees including the WHO committees relating to vaccine policy, reference standards, testing and validation studies. He was the president of the Developing Countries Vaccine Manufacturers Network, an alliance of vaccine manufacturers from developing countries, between 2004 and 2008. He was also a member of the board of GAVI vaccine alliance and was a member of its program and policy committee. He was also a member of the European Vaccine Institute and was a member of the Indian government's expert committee on vaccines and other biologicals and a member of the Indian Pharmacopoeia Commission. He was the co-chairman of the Confederation of Indian Industry's national committee on biotechnology for 2019–20.

Dr. Muhammed Majeed

Dr. Muhammed Majeed (September 25, 1948 – March 13, 2024) was a pioneering scientist, entrepreneur, and philanthropist who made significant contributions to the nutraceutical and cosmeceutical industries. Born in Kerala, India, he pursued higher education in the United States, earning a Master's degree in Industrial Pharmacy from Long Island University and a Ph.D. in Industrial Chemistry. His academic background laid a strong foundation for his future endeavors in integrating traditional Ayurvedic knowledge with modern scientific research.​

In 1988, Dr. Majeed founded Sabinsa Corporation in the United States, focusing on the research and development of standardized herbal extracts and fine chemicals. His vision was to bring the rich heritage of Indian Ayurveda to the global stage through scientifically validated products. In 1991, he established Sami Labs Limited (now known as Sami-Sabinsa Group Limited) in Bengaluru, India, serving as a research and manufacturing hub. Under his leadership, the company expanded to operate seven manufacturing facilities and employed over 1,400 individuals, including more than 120 senior scientists dedicated to exploring the mechanisms of action and physiological effects of herbs. ​

Dr. Majeed's innovative approach led to the development of numerous patented products that bridged the gap between traditional herbal medicine and contemporary pharmaceutical needs. His commitment to quality and efficacy earned him several prestigious awards. In 2023, he was honored with the Lifetime Achievement Award at the 1st Kerala Pharmaceutical Congress, recognizing his invaluable contributions to shaping the Indian nutraceuticals industry and promoting preventive healthcare. Posthumously, in June 2024, he received the Times Business Awards Lifetime Achievement Award for his exemplary contributions to nutraceuticals, cosmeceuticals, and philanthropy. ​

Beyond his business accomplishments, Dr. Majeed was deeply committed to philanthropy, focusing on education and healthcare initiatives in India. He established the Dr. Majeed Foundation to support various charitable activities, reflecting his belief in giving back to society and enriching human life. His legacy continues through the ongoing work of the Sami-Sabinsa Group and the numerous lives touched by his philanthropic efforts.

Dr. S.K. Punshi

Dr. S.K. Punshi is a distinguished Indian physician renowned for his expertise in dermatology, particularly in the treatment of vitiligo (leucoderma). He holds an MBBS from Indore and a DDV from Bombay, along with fellowships from FIMS and FDS (London). His clinic is located at Rajkamal Chowk, Amravati, Maharashtra. ​

Dr. Punshi's pioneering work includes the introduction of placental extract therapy for vitiligo, a significant advancement in dermatological treatments. His research is widely cited in various dermatology journals and books, reflecting his substantial contributions to the field. ​
bhagatkanwarram.com

Beyond his clinical practice, Dr. Punshi has been actively involved in social initiatives. Over the past 25 years in Amravati, he has participated in numerous diagnostic camps organized by the Indian Medical Association (IMA), Jaycees, Lions Club, and other social organizations, providing free examinations to thousands of patients. ​

Dr. Punshi has also contributed to public awareness through media engagements. He has delivered talks on "Leucoderma and Society" on All India Radio's Nagpur Station and was interviewed by Bombay Doordarshan in a national Hindi program discussing leucoderma. Despite his numerous achievements, Dr. Punshi remains humble, attributing his work to divine will and maintaining a holistic approach to life. ​

In summary, Dr. S.K. Punshi is a dedicated physician whose innovative treatments, community service, and public education efforts have significantly impacted the field of dermatology and patient care in India.

Dr. Nitya Anand

Dr. Nitya Anand (1 January 1925 – 27 January 2024) was a distinguished Indian medicinal chemist renowned for his significant contributions to drug research and development. Born in Lyallpur, Punjab Province (now Faisalabad, Pakistan), he pursued higher education in chemistry, earning a Master's degree from St. Stephen's College in 1945 and a Ph.D. in organic chemistry from the Institute of Chemical Technology in Mumbai in 1948. He furthered his studies with a second Ph.D. from St. John's College, Cambridge University, and conducted post-doctoral research at Harvard Medical School in 1958. ​

In 1951, Dr. Anand joined the Central Drug Research Institute (CDRI) in Lucknow, where he served as the director from 1974 to 1984. His tenure at CDRI was marked by groundbreaking work, including the development of 'Centchroman' (branded as 'Saheli'), the world's first non-steroidal, non-hormonal, once-a-week oral contraceptive. This innovative drug, incorporated into India's National Family Planning Programme in 2016, offered a safer contraceptive option and represented a significant advancement in the field. ​

Dr. Anand's research interests centered on the design, discovery, and development of new drugs using synthetic chemistry approaches, focusing on drug-receptor interactions and metabolism. He published over 400 research articles, held more than 130 patents, and co-authored the book "Art in Organic Synthesis" with Jasjit S. Bindra in 1969. His expertise and leadership extended beyond CDRI; he served as chairman of the Ranbaxy Science Foundation and was a fellow of the Indian National Science Academy. ​

In recognition of his outstanding contributions to science and medicine, Dr. Anand was awarded the Padma Shri by the Government of India in 2012. His legacy continues through his work and the inspiration he provided to future generations of scientists. Notably, his daughter, Dr. Sonia Nityanand, has followed in his illustrious footsteps, serving as the Vice-Chancellor of King George's Medical University and also being honored with the Padma Shri in 2025. ​

Dr. Nitya Anand's pioneering efforts have left an indelible mark on India's pharmaceutical industry, exemplifying a lifelong commitment to scientific excellence and innovation.​

Dr. Kallam Anji Reddy

Dr. Kallam Anji Reddy (10 August 1941 – 15 March 2013) was a pioneering Indian entrepreneur and scientist who significantly impacted the global pharmaceutical industry. Born in Tadepalli, Andhra Pradesh, he completed his Bachelor of Science degree from A.C. College in Guntur in 1958 and later earned a B.Sc. (Tech) in Pharmaceuticals and Fine Chemicals from the University Department of Chemical Technology, Mumbai. He further pursued a Ph.D. in chemical engineering from the National Chemical Laboratory, Pune, in 1969. ​

In 1984, Dr. Reddy founded Dr. Reddy's Laboratories, transforming it into a global pharmaceutical powerhouse renowned for its innovative approaches to drug development and commitment to affordable healthcare. His leadership propelled the company to international markets, making significant strides in both generic and proprietary medicine sectors. ​

Dr. Reddy's contributions extended beyond his company. In 1996, he established the Dr. Reddy's Foundation, aiming to provide quality education and skill development to underprivileged youth, thereby enhancing their employment prospects. His dedication to social causes reflected his belief in inclusive growth and societal well-being.​

Throughout his illustrious career, Dr. Reddy received several prestigious honors, including the Padma Shri in 2001 and the Padma Bhushan in 2011, recognizing his invaluable contributions to the Indian pharmaceutical industry. In 2012, he was honored with the Lifetime Achievement in Health Award at the Asian Voice Political and Public Life Awards in Britain for his unwavering commitment to medical research and improving lives. His legacy continues to inspire innovation and social responsibility within the pharmaceutical sector.

Dr. Girish Sahni

Dr. Girish Sahni (1956 – August 19, 2024) was a distinguished Indian scientist renowned for his significant contributions to protein engineering, molecular biology, biotechnology, and enzymology. Born on March 2, 1956, he completed his Ph.D. at the Indian Institute of Science (IISc), Bangalore, in 1984. His research primarily focused on protein cardiovascular drugs, especially 'clot busters,' and their mechanisms within the human body. ​

Dr. Sahni began his career at the CSIR-Institute of Microbial Technology (IMTECH) in Chandigarh in 1991, ascending to the position of Director in 2005. In 2015, he was appointed Director General of the Council of Scientific and Industrial Research (CSIR) and Secretary of the Department of Scientific and Industrial Research (DSIR), roles he held until 2018. During his tenure, he emphasized translational research and fostered collaborations between scientific institutions and industry. ​

One of his notable achievements was the development of a clot-specific streptokinase, a breakthrough in cardiovascular treatment. In 2006, the licensing rights for this drug were acquired by Nostrum Pharmaceuticals in New Jersey, USA, marking a significant milestone in Indian academia's technology transfers. ​

Dr. Sahni was elected as a Fellow of the Indian Academy of Sciences in 2001, reflecting his esteemed status in the scientific community. His legacy continues to inspire advancements in biotechnology and protein engineering, with his work having a lasting impact on cardiovascular treatments and scientific research in India.

Dilip Girdharlal Shah

Dilip Girdharlal Shah, affectionately known as DG Shah, was a pioneering figure in India's pharmaceutical industry, renowned for his advocacy of generic medicines and his instrumental role in shaping public health policies. Born in 1941, Shah was part of the inaugural graduating class of the Indian Institute of Management, Ahmedabad (IIMA) in 1966, where he met his future wife, Smita Dalal, marking the institute's first matrimonial alliance. ​

Shah commenced his professional journey with Pfizer in 1967, dedicating three decades to the company and ascending to the position of Commercial Director and board member for Pfizer India. In 1999, recognizing the need for a unified voice for domestic pharmaceutical companies, he founded the Indian Pharmaceutical Alliance (IPA). Under his leadership, the IPA championed the cause of generic drugs and opposed stringent intellectual property rights that could hinder access to affordable medicines. The alliance grew to encompass 24 leading Indian pharmaceutical companies, collectively representing a significant portion of the domestic market and exports. ​

Beyond the IPA, Shah established the Vision Consulting Group, offering expertise in public policy, strategy, and planning. He served in various advisory capacities, including as Chair of the International Generic Pharmaceutical Alliance (IGPA) for two terms and as a director for several pharmaceutical companies. His contributions were pivotal in shaping India's patent laws to favor affordable medicines while aligning with international agreements. ​

Shah's legacy continues through the "DG Shah Award for Best Public Policy Paper," instituted posthumously at IIMA to honor his immense contributions to public policy. His life's work significantly bolstered India's position as a global leader in generic medicines, ensuring access to affordable healthcare for millions worldwide.

Devinder Pal

Devinder Pal was a distinguished figure in the Indian pharmaceutical industry, with a career spanning over five decades. Born on October 21, 1936, in Kohat, Punjab, India, he laid a strong educational foundation that propelled him into various leadership roles within the sector. His journey included significant positions at Warner-Lambert, Elder Pharmaceuticals, and ultimately, the establishment of his own consultancy, Catalyst Pharma Consult. ​

At Warner-Lambert, a company known for its diverse pharmaceutical and consumer healthcare products, Pal contributed to the organization's growth and innovation. His tenure there was marked by strategic initiatives that enhanced the company's market presence. Following this, he played a pivotal role at Elder Pharmaceuticals, further solidifying his reputation as a leader capable of steering companies toward success in the competitive pharmaceutical landscape.​

In 1985, Pal became a certified trainer for Warner-Lambert's leadership program, reflecting his commitment to fostering talent and leadership within the industry. His expertise and dedication were recognized by several prestigious awards:​

Fellowship of the Indian Pharmaceutical Association (1994): This honor acknowledged his significant contributions to the advancement of the pharmaceutical profession in India.​

Pharma Excellence Professional Award (2000): Presented by Pharma Business and Technology, India, this award celebrated his exceptional professional achievements in the pharmaceutical sector.​

Eminent Pharmacist Award (2003): This accolade recognized his outstanding contributions to the field of pharmacy, underscoring his dedication and impact on the industry.​

Pal's enduring commitment to the pharmaceutical industry continues to influence and inspire professionals and organizations within the sector. His legacy is further cemented by the Indian Pharmaceutical Association's establishment of the "IPA – Devinder Pal National Elocution Competition," aimed at fostering communication skills among pharmacy students. ​

Devinder Pal's journey reflects a legacy of leadership, innovation, and unwavering dedication to the advancement of the pharmaceutical industry. His contributions have left an indelible mark, inspiring future generations of professionals in the field.

Desh Bandhu Gupta

Desh Bandhu Gupta (8 February 1938 – 26 June 2017) was an Indian entrepreneur and philanthropist, best known as the founder of Lupin Limited. Born in Rajasthan, he earned a master’s degree in chemistry and started his career as an associate professor before venturing into the pharmaceutical industry. In 1968, he founded Lupin with just ₹5,000, later securing a loan to establish a manufacturing facility. Under his leadership, Lupin grew into a global pharmaceutical powerhouse, especially in the U.S. and Japanese markets.

Beyond business, Gupta was dedicated to social welfare. He established the Lupin Human Welfare & Research Foundation in 1988, positively impacting millions in rural India through development programs. His contributions were widely recognized, earning him awards like the Ernst & Young Entrepreneur of the Year (2011) and Frost & Sullivan Lifetime Achievement Award (2013). In 2018, he was posthumously inducted into the CNBC TV18 India Business Leader Awards Hall of Fame.

In addition to his business achievements, Gupta was deeply committed to social welfare. In October 1988, he established the Lupin Human Welfare & Research Foundation (LHWRF) with the goal of creating a sustainable model for rural development. The foundation aimed to uplift families living below the poverty line in rural India by focusing on holistic development programs that created opportunities and infrastructure, empowering rural communities, and ensuring their inclusion in the nation's economic progress. The Lupin Foundation impacted the lives of 2.8 million people across approximately 3,500 villages in nine states, including Rajasthan, Maharashtra, Madhya Pradesh, Goa, Uttarakhand, Gujarat, Jammu, Andhra Pradesh, and Sikkim.

D. Gupta was married to Manju and resided in Mumbai. He was survived by his wife and five children: four daughters and one son. His daughter Vinita D. Gupta serves as the Group President & CEO, based in the United States, and his son Nilesh Gupta is the Managing Director based in India. Gupta passed away on 26 June 2017 in Mumbai at the age of 79.

Bhaskarrao Govind Sandu

Bhaskarrao Govind Sandu was a prominent figure in the Ayurvedic pharmaceutical industry, serving as the Chairman of Sandu Pharmaceuticals. Born in 1937, he dedicated over six decades to advancing Ayurvedic medicine, significantly contributing to its growth and recognition. Under his leadership, Sandu Pharmaceuticals, a company with a legacy spanning more than 120 years, flourished and became a trusted name in the industry. ​

Throughout his tenure, Bhaskarrao Sandu was instrumental in modernizing the production processes of Ayurvedic medicines, ensuring they met contemporary standards while preserving traditional wisdom. His commitment to quality and efficacy helped the company expand its product range and reach a broader audience, both domestically and internationally.​

Beyond his corporate achievements, Sandu was known for his dedication to promoting Ayurveda as a holistic approach to health and wellness. He actively participated in various industry forums and was a respected voice advocating for the integration of Ayurvedic practices into mainstream healthcare.​

Despite extensive research, specific details regarding awards or formal recognitions bestowed upon Bhaskarrao Govind Sandu remain limited. However, his enduring impact on the Ayurvedic industry and his commitment to promoting traditional medicine stand as a testament to his contributions.

Bhai Mohan Singh

Bhai Mohan Singh (30 December 1917 – 27 March 2006) was a pioneering Indian entrepreneur, best known for transforming Ranbaxy Laboratories into one of India's largest pharmaceutical companies. Born in Rawalpindi, British India (now in Pakistan), Singh began his business career during World War II with a construction enterprise. Following the partition in 1947, he relocated to New Delhi, where he ventured into various businesses. ​

In 1952, Singh acquired Ranbaxy, a small pharmaceutical company, from his cousins Ranjit Singh and Gurbax Singh, whose names combined to form 'Ranbaxy'. Under his leadership, Ranbaxy evolved from a modest operation into a global pharmaceutical giant, known for its innovative approaches and significant contributions to the industry. ​

Singh's contributions extended beyond the pharmaceutical sector. He served as the Vice President of the New Delhi Municipal Corporation (NDMC), where his efforts in civic matters were recognized with the prestigious Padma Shri award. His dedication to industrial development, particularly in Punjab, led to the establishment of Max India Ltd, further cementing his legacy as a visionary industrialist.

Bhai Mohan Singh's journey from a partition-era entrepreneur to a titan of the pharmaceutical industry exemplifies resilience and vision, leaving an indelible mark on India's industrial landscape.

Anand Chandavarkar

Anand Chandavarkar was a visionary entrepreneur who founded Fairdeal Corporation in 1936, a company that would later evolve into FDC Limited, a prominent Indian pharmaceutical firm. His ambition was to make India self-reliant in healthcare, and under his leadership, the company developed a portfolio of products that became synonymous with their categories. ​

FDC Limited specializes in various therapeutic segments, including anti-infectives, gastrointestinal, ophthalmic, vitamins, minerals, dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, and analgesics. The company also produces active pharmaceutical ingredients and nutraceuticals, serving both domestic and international markets. ​

Anand Chandavarkar's legacy continues through the leadership of his son, Mr. Mohan Anand Chandavarkar, who serves as the Managing Director of FDC Limited. Mohan joined the company in 1958 as an apprentice in the laboratory and has been instrumental in its growth and diversification. ​

Through their dedication and strategic vision, the Chandavarkar family has significantly contributed to India's pharmaceutical industry, ensuring the availability of quality healthcare products and reinforcing the nation's self-reliance in this critical sector.

Amar Lulla

Amar Lulla was a key figure in the Indian pharmaceutical industry, serving as the Joint Managing Director of Cipla. He played a crucial role in expanding Cipla’s presence globally, making essential medicines more affordable and accessible, particularly in developing countries. Under his leadership, Cipla became a pioneer in producing cost-effective HIV/AIDS medications, significantly impacting global healthcare. His efforts in innovation and market expansion helped Cipla grow into one of India’s most respected pharmaceutical companies. Lulla was known for his sharp business acumen and commitment to affordable healthcare. His contributions to the industry have left a lasting legacy, ensuring that millions worldwide continue to benefit from life-saving medicines.